Social Anxiety Disorder Study Of Paroxetine
NCT00318669 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 390
Last updated 2013-04-15
Summary
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).
Conditions
- Social Phobia
Interventions
- DRUG
-
Paroxetine hydrochloride hydrate
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-12-31
- Primary Completion
- 2006-11-30
- Completion
- 2006-11-30
Countries
- Japan
Study Locations
More Related Trials
-
Study Of Generalized Anxiety Disorder
NCT00135525 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Of Patients With Social Anxiety Disorder
NCT00397722 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
NCT00273039 ·Status: COMPLETED ·Phase: PHASE2
-
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
NCT00470483 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
NCT02432703 ·Status: COMPLETED ·Phase: PHASE2
-
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00332891 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00677352 ·Status: COMPLETED ·Phase: PHASE4
-
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
NCT05030350 ·Status: TERMINATED ·Phase: PHASE3
-
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00266747 ·Status: COMPLETED ·Phase: PHASE3
-
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
NCT00658372 ·Status: TERMINATED ·Phase: PHASE3
-
RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo
NCT00184106 ·Status: COMPLETED ·Phase: PHASE4
-
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
NCT02622958 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of ONO-1110 in Patients With Social Anxiety Disorder
NCT06805565 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
NCT00658762 ·Status: TERMINATED ·Phase: PHASE3
-
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
NCT00658008 ·Status: TERMINATED ·Phase: PHASE3
-
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
NCT00560612 ·Status: COMPLETED ·Phase: PHASE4
-
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
NCT01470469 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder
NCT00397098 ·Status: TERMINATED ·Phase: PHASE3
-
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
NCT00555139 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
NCT00191022 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
NCT00294346 ·Status: COMPLETED ·Phase: PHASE2
-
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
NCT00616655 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
NCT05193409 ·Status: COMPLETED ·Phase: PHASE2